: Evaluation of human PrP expression levels in the humanised transgenic mouse model used for substrate and the ability to support in vitro conversion by PMCA. (A) Brain material derived from transgenic mouse containing the human form of the prion protein homozygous for methionine at codon 129 (Tg brain substrate), and non-CJD human postmortem brain tissue with an equivalent codon 129 polymorphism (Human brain substrate), were homogenised at 10% weight/volume (10% w/v). The samples were further diluted in conversion buffer to compare the total PrP expression levels (dilutions: 1/80, 1/160, 1/320). Detection of human PrP was assessed by Western blotting using 3F4 mAb. The human PrP was detected in the form of two major bands in the range of 20-40-kDa molecular mass. (B) Amplification of vCJD prions using the standard protocol of PMCA. Serial dilutions of 10% w/v vCJD human brain homogenate (1x10 -4 , 1x10 -5 , 1x10 -6 , and 1x10 -7 ) were diluted in substrate and amplified for 96 cycles (48 hrs). The amplification of the serially diluted vCJD samples were performed in triplicate (Set1, Set 2 and Set 3). Aliquots of the seeded amplification mixture were retained (Frozen samples "F") for comparison to the samples subject to amplification (Sonicate samples "S"). Samples were treated with proteinase K, and PrP res was evaluated by Western blotting using 3F4 mAb. The amplified sample showed a type 2B banding pattern typically observed in vCJD. Reference molecular marker have been included. Molecular mass of electrophoretic markers is given in kilodaltons (kDa). At least three technical repeats were performed with similar results and a representative Western blot presented. -5 , 1x10 -6 , 1x10 -7 1x10 -8 , 1x10 -9 , 1x10 -10 , and 1x10 -11 ) were amplified by hsPMCA for 96 cycles (48 hrs). Amplification of the serially diluted vCJD samples by hsPMCA was performed in triplicate (Set1, Set 2 and Set 3). Samples retained as frozen ("F") or subjected to amplification by sonication ("S") were proteinase K digested and PrP res was evaluated by Western blotting using 3F4 mAb. The amplified sample showed a type 2B banding pattern typically observed in vCJD. (B) Amplification of sCJD MM1 prions derived from 10% w/v human brain homogenate diluted in codon 129MM transgenic mouse substrate (2.5x10 -1 , 2.5x10 -2 , 2.5x10 -3 and 2.5x10 -4 ) and subjected to hsPMCA for 96 cycles (C) Amplification of sCJD MV2K prions derived from 10% w/v human brain homogenate diluted in codon 129MM transgenic mouse substrate (2x10 -1 , 2x10 -2 , 2x10 -3 and 2x10 -4 ) and subjected to hsPMCA for 96 cycles. Reference molecular marker have been included. Molecular mass of electrophoretic markers is given in kilodaltons (kDa). At least three technical repeats for vCJD and 3 confirmed sCJD MM1 and MV2K cases were evaluated with similar results. A representative Western blot is presented.
